Table 2.
Characteristics of patients with and without fragility fractures.
| Women (n = 170) |
Men (n = 59) |
|||||
|---|---|---|---|---|---|---|
| premenoposal (n = 84) |
postmenoposal (n = 86) |
|||||
| Fracture (n = 5) | Fracture-free (n = 79) | Fracture (n = 36) | Fracture-free (n = 50) | Fracture (n = 16) | Fracture-free (n = 43) | |
| Bisphosphonate prescription | 1 (25%) | 27 (34.2%) | 24 (66.7%) | 36 (72%) | 8 (50%) | 26 (60.5%) |
| Active Vitamin D prescription | 3 (60%) | 53 (67.1%) | 17 (47.2%) | 32 (64%) | 9 (56.3%) | 15 (34.9%) |
| Methylprednisolone pulse therapy | 5 (100%) | 43 (54.4%) | 17 (47.2%) | 16 (32%) | 3 (18.8%) | 21 (48.8%) |
| Prior high-dose GC treatment | 4 (80%) | 26 (32.9%) | 5 (13.9%) | 4 (8%) | 6 (37.5%) | 5 (11.6%) |
| FRAX (major fractures) | − | − | 14.5 | 10 [4.9–16.8] | 8.5 [5.0–12.0]1 | 6.1 [4.2–8.5]1 |
1
FRAX 10-year probability of a major osteoporotic fracture is calculated for male over 40 years of age.